Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care.
Company profile
Ticker
CTXR
Exchange
Website
CEO
Myron Holubiak
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Trail One, Inc., TrailOne, Inc.
SEC CIK
Corporate docs
Subsidiaries
Citius Pharmaceuticals, LLC • Leonard-Meron Biosciences, Inc. • NoveCite, Inc. • Citius Acquisition Corp. ...
CTXR stock data
Latest filings (excl ownership)
8-K
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
22 Dec 22
DEFA14A
Additional proxy soliciting materials
22 Dec 22
DEF 14A
Definitive proxy
22 Dec 22
10-K
2022 FY
Annual report
22 Dec 22
8-K
Other Events
1 Dec 22
8-K
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program
21 Nov 22
8-K
Other Events
28 Sep 22
8-K
I/ONTAK plus PD-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients
22 Sep 22
8-K
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2022 Financial Results and Provides Business Update
11 Aug 22
10-Q
2022 Q3
Quarterly report
11 Aug 22
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 41.71 mm | 41.71 mm | 41.71 mm | 41.71 mm | 41.71 mm | 41.71 mm |
| Cash burn (monthly) | 2.11 mm | 2.36 mm | 2.52 mm | 2.78 mm | 2.11 mm | 2.36 mm |
| Cash used (since last report) | 8.71 mm | 9.75 mm | 10.39 mm | 11.46 mm | 8.71 mm | 9.75 mm |
| Cash remaining | 33.00 mm | 31.96 mm | 31.33 mm | 30.25 mm | 33.00 mm | 31.96 mm |
| Runway (months of cash) | 15.6 | 13.5 | 12.4 | 10.9 | 15.6 | 13.5 |
Institutional ownership, Q3 2022
9.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 54 |
| Opened positions | 13 |
| Closed positions | 17 |
| Increased positions | 7 |
| Reduced positions | 14 |
| 13F shares | Current |
|---|---|
| Total value | 32.27 mm |
| Total shares | 13.27 mm |
| Total puts | 50.10 k |
| Total calls | 650.50 k |
| Total put/call ratio | 0.1 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 5.81 mm | $7.04 mm |
| BLK Blackrock | 2.33 mm | $2.82 mm |
| Geode Capital Management | 1.32 mm | $1.60 mm |
| Millennium Management | 784.78 k | $950.00 k |
| Renaissance Technologies | 390.77 k | $473.00 k |
| Ergoteles | 380.06 k | $460.00 k |
| NTRS Northern Trust | 238.23 k | $289.00 k |
| Inspire Advisors | 198.41 k | $240.00 k |
| HighTower Advisors | 170.62 k | $206.00 k |
| Wealth Advisory Solutions | 156.85 k | $190.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Oct 22 | Webb Carol | Options to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.25 | 75,000 | 93.75 k | 75,000 |
| 4 Oct 22 | Myron Czuczman | Stock Option (Right to Purchase Common Stock) Common Stock | Grant | Acquire A | No | No | 1.25 | 300,000 | 375.00 k | 300,000 |
| 4 Oct 22 | Safir Howard | Options to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.25 | 75,000 | 93.75 k | 75,000 |
| 4 Oct 22 | Holuka Eugene Myron | Options to Purchase Common Stock Common Stock | Grant | Acquire A | No | No | 1.25 | 75,000 | 93.75 k | 75,000 |
| 4 Oct 22 | Jaime Bartushak | Stock Option (Right to Purchase Common Stock) Common Stock | Grant | Acquire A | No | No | 1.25 | 300,000 | 375.00 k | 300,000 |
News
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
18 Jan 23
Why Arcimoto Shares Are Trading Lower By 44%; Here Are 20 Stocks Moving Premarket
18 Jan 23
12 Health Care Stocks Moving In Monday's Intraday Session
26 Dec 22
12 Health Care Stocks Moving In Friday's Pre-Market Session
23 Dec 22
Citius Pharmaceuticals, Inc. Announces U.S. FDA Acceptance Of Biologics License Application Of Denileukin Diftitox For The Treatment Of Patients With Persistent Or Recurrent Cutaneous T-Cell Lymphoma
1 Dec 22
Press releases
Sidoti's January Micro-Cap Conference
17 Jan 23
Citius Pharmaceuticals to Present at the Sidoti Micro-Cap Virtual Conference on January 18, 2023
11 Jan 23
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update
22 Dec 22
Citius Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Biologics License Application of Denileukin Diftitox for the Treatment of Patients with Persistent or Recurrent Cutaneous T-Cell Lymphoma
1 Dec 22
Citius Pharmaceuticals, Inc. Secures $3.6 million through New Jersey Economic Development Program
21 Nov 22